Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1992 Jun;60(6):2218–2224. doi: 10.1128/iai.60.6.2218-2224.1992

Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

K L Kotloff 1, D A Herrington 1, T L Hale 1, J W Newland 1, L Van De Verg 1, J P Cogan 1, P J Snoy 1, J C Sadoff 1, S B Formal 1, M M Levine 1
PMCID: PMC257146  PMID: 1587589

Abstract

A live, oral Shigella vaccine, constructed by transfer of the 140-MDa invasiveness plasmid from Shigella flexneri 5 and the chromosomal genes encoding the group- and type-specific O antigen of S. flexneri 2a to Escherichia coli K-12, was tested in humans. Designated EcSf2a-1, this vaccine produced adverse reactions (fever, diarrhea, or dysentery) in 4 (31%) of 13 subjects who ingested a single dose of 1.0 x 10(9) CFU, while at better-tolerated doses (5.0 x 10(6) to 5.0 x 10(7) CFU), it provided no significant protection against challenge with S. flexneri 2a. A further-attenuated aroD mutant derivative, EcSf2a-2, was then tested. Rhesus monkeys that received EcSf2a-2 in three oral doses of ca. 1.5 x 10(11) CFU experienced no increase in gastrointestinal symptoms compared with a control group that received an E. coli K-12 placebo. Compared with controls, the vaccinated monkeys were protected against shigellosis after challenge with S. flexneri 2a (60% efficacy; P = 0.001). In humans, EcSf2a-2 was well tolerated at inocula ranging from 5.0 x 10(6) to 2.1 x 10(9) CFU. However, after a single dose of 2.5 x 10(9) CFU, 4 (17%) of 23 subjects experienced adverse reactions, including fever (3 subjects) and diarrhea (209 ml) (1 subject), and after a single dose of 1.8 x 10(10) CFU, 2 of 4 subjects developed dysentery. Recipients of three doses of 1.2 to 2.5 x 10(9) CFU had significant rises in serum antibody to lipopolysaccharide (61%) and invasiveness plasmid antigens (44%) and in gut-derived immunoglobulin A antibody-secreting cells specific for lipopolysaccharide (100%) and invasiveness plasmid antigens (60%). Despite its immunogenicity, the vaccine conferred only 36% protection against illness (fever, diarrhea, or dysentery) induced by experimental challenge (P = 0.17). These findings illustrate the use of an epithelial cell-invasive E. coli strain as a carrier for Shigella antigens. Future studies must explore dosing regimens that might optimize the protective effects of the vaccine while eliminating adverse clinical reactions.

Full text

PDF
2218

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black R. E., Levine M. M., Clements M. L., Losonsky G., Herrington D., Berman S., Formal S. B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis. 1987 Jun;155(6):1260–1265. doi: 10.1093/infdis/155.6.1260. [DOI] [PubMed] [Google Scholar]
  2. Choudari C. P., Mathan M., Rajan D. P., Raghavan R., Mathan V. I. A correlative study of etiology, clinical features and rectal mucosal pathology in adults with acute infectious diarrhea in southern India. Pathology. 1985 Jul;17(3):443–450. doi: 10.3109/00313028509105498. [DOI] [PubMed] [Google Scholar]
  3. Cohen D., Green M. S., Block C., Slepon R., Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol. 1991 Feb;29(2):386–389. doi: 10.1128/jcm.29.2.386-389.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DuPont H. L., Hornick R. B., Snyder M. J., Libonati J. P., Formal S. B., Gangarosa E. J. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis. 1972 Jan;125(1):5–11. doi: 10.1093/infdis/125.1.5. [DOI] [PubMed] [Google Scholar]
  5. DuPont H. L., Hornick R. B., Snyder M. J., Libonati J. P., Formal S. B., Gangarosa E. J. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis. 1972 Jan;125(1):12–16. doi: 10.1093/infdis/125.1.12. [DOI] [PubMed] [Google Scholar]
  6. DuPont H. L., Levine M. M., Hornick R. B., Formal S. B. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis. 1989 Jun;159(6):1126–1128. doi: 10.1093/infdis/159.6.1126. [DOI] [PubMed] [Google Scholar]
  7. Fasano A., Kay B. A., Russell R. G., Maneval D. R., Jr, Levin M. M. Enterotoxin and cytotoxin production by enteroinvasive Escherichia coli. Infect Immun. 1990 Nov;58(11):3717–3723. doi: 10.1128/iai.58.11.3717-3723.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ferreccio C., Levine M. M., Rodriguez H., Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis. 1989 Apr;159(4):766–769. doi: 10.1093/infdis/159.4.766. [DOI] [PubMed] [Google Scholar]
  9. Ferreccio C., Prado V., Ojeda A., Cayyazo M., Abrego P., Guers L., Levine M. M. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol. 1991 Sep 15;134(6):614–627. doi: 10.1093/oxfordjournals.aje.a116134. [DOI] [PubMed] [Google Scholar]
  10. Formal S. B., Hale T. L., Kapfer C., Cogan J. P., Snoy P. J., Chung R., Wingfield M. E., Elisberg B. L., Baron L. S. Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen. Infect Immun. 1984 Nov;46(2):465–469. doi: 10.1128/iai.46.2.465-469.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hale T. L., Formal S. B. Protein synthesis in HeLa or Henle 407 cells infected with Shigella dysenteriae 1, Shigella flexneri 2a, or Salmonella typhimurium W118. Infect Immun. 1981 Apr;32(1):137–144. doi: 10.1128/iai.32.1.137-144.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hartman A. B., Powell C. J., Schultz C. L., Oaks E. V., Eckels K. H. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect Immun. 1991 Nov;59(11):4075–4083. doi: 10.1128/iai.59.11.4075-4083.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Herrington D. A., Van de Verg L., Formal S. B., Hale T. L., Tall B. D., Cryz S. J., Tramont E. C., Levine M. M. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 1990 Aug;8(4):353–357. doi: 10.1016/0264-410x(90)90094-3. [DOI] [PubMed] [Google Scholar]
  14. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine. 1990 Aug;8(4):321–326. doi: 10.1016/0264-410x(90)90088-4. [DOI] [PubMed] [Google Scholar]
  15. Kärnell A., Stocker B. A., Katakura S., Sweiha H., Reinholt F. P., Cam P. D., Trach D. D., Lindberg A. A. An auxotrophic live oral Shigella flexneri vaccine: development and testing. Rev Infect Dis. 1991 Mar-Apr;13 (Suppl 4):S357–S361. doi: 10.1093/clinids/13.supplement_4.s357. [DOI] [PubMed] [Google Scholar]
  16. Levine M. M., Black R. E., Clements M. L., Lanata C., Sears S., Honda T., Young C. R., Finkelstein R. A. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun. 1984 Feb;43(2):515–522. doi: 10.1128/iai.43.2.515-522.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Levine M. M., Dupont H. L., Gangarosa E. J., Hornick R. B., Snyder M. J., Libonati J. P., Glaser K., Formal S. B. Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines. Am J Epidemiol. 1972 Jul;96(1):40–49. doi: 10.1093/oxfordjournals.aje.a121431. [DOI] [PubMed] [Google Scholar]
  18. Levine M. M., Woodward W. E., Formal S. B., Gemski P., Jr, DuPont H. L., Hornick R. B., Snyder M. J. Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri. J Infect Dis. 1977 Oct;136(4):577–582. doi: 10.1093/infdis/136.4.577. [DOI] [PubMed] [Google Scholar]
  19. Mathan V. I., Penny G. R., Mathan M. M., Rowley D. Bacterial lipopolysaccharide-induced intestinal microvascular lesions leading to acute diarrhea. J Clin Invest. 1988 Nov;82(5):1714–1721. doi: 10.1172/JCI113785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Meitert T., Pencu E., Ciudin L., Tonciu M. Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati). Arch Roum Pathol Exp Microbiol. 1984 Jul-Dec;43(3-4):251–278. [PubMed] [Google Scholar]
  21. Mel D. M., Arsic B. L., Radovanovic M. L., Litvinjenko S. A. Live oral Shigella vaccine: vaccination schedule and the effect of booster dose. Acta Microbiol Acad Sci Hung. 1974;21(1-2):109–114. [PubMed] [Google Scholar]
  22. Mel D. M., Arsić B. L., Nikolić B. D., Radovanić M. L. Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. Bull World Health Organ. 1968;39(3):375–380. [PMC free article] [PubMed] [Google Scholar]
  23. Mel D. M., Terzin A. L., Vuksić L. Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull World Health Organ. 1965;32(5):647–655. [PMC free article] [PubMed] [Google Scholar]
  24. Mel D., Gangarosa E. J., Radovanovic M. L., Arsic B. L., Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull World Health Organ. 1971;45(4):457–464. [PMC free article] [PubMed] [Google Scholar]
  25. Morris G. K., Koehler J. A., Gangarosa E. J., Sharrar R. G. Comparison of media for direct isolation and transport of Shigellae from Fecal specimens. Appl Microbiol. 1970 Mar;19(3):434–437. doi: 10.1128/am.19.3.434-437.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Oaks E. V., Hale T. L., Formal S. B. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect Immun. 1986 Jul;53(1):57–63. doi: 10.1128/iai.53.1.57-63.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pál T., Newland J. W., Tall B. D., Formal S. B., Hale T. L. Intracellular spread of Shigella flexneri associated with the kcpA locus and a 140-kilodalton protein. Infect Immun. 1989 Feb;57(2):477–486. doi: 10.1128/iai.57.2.477-486.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sansonetti P. J., Hale T. L., Dammin G. J., Kapfer C., Collins H. H., Jr, Formal S. B. Alterations in the pathogenicity of Escherichia coli K-12 after transfer of plasmid and chromosomal genes from Shigella flexneri. Infect Immun. 1983 Mar;39(3):1392–1402. doi: 10.1128/iai.39.3.1392-1402.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Seid R. C., Jr, Kopecko D. J., Sadoff J. C., Schneider H., Baron L. S., Formal S. B. Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. J Biol Chem. 1984 Jul 25;259(14):9028–9034. [PubMed] [Google Scholar]
  30. Van de Verg L., Herrington D. A., Murphy J. R., Wasserman S. S., Formal S. B., Levine M. M. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun. 1990 Jun;58(6):2002–2004. doi: 10.1128/iai.58.6.2002-2004.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES